Confronting Covid-19 by exploring the possibility of vaccinating with live SARS-CoV-2 virus itself, via a route that would reduce the incidence of pulmonary complications [version 1; peer review: 2 approved]

This article proposes that one should explore whether the pulmonary complications of Covid-19 can be reduced or avoided by bypassing the airway entry of the SARS-CoV-2 virus. This could possibly be achieved by injecting live SARS-CoV-2 virus intradermal (ID), subcutaneous, intra-muscular (IM) or int...

Full description

Bibliographic Details
Main Author: Etienne Joly
Format: Article
Language:English
Published: F1000 Research Ltd 2020-04-01
Series:F1000Research
Online Access:https://f1000research.com/articles/9-309/v1
id doaj-82dafd7263c644df9689218d04681b88
record_format Article
spelling doaj-82dafd7263c644df9689218d04681b882021-05-11T12:23:35ZengF1000 Research LtdF1000Research2046-14022020-04-01910.12688/f1000research.23480.125911Confronting Covid-19 by exploring the possibility of vaccinating with live SARS-CoV-2 virus itself, via a route that would reduce the incidence of pulmonary complications [version 1; peer review: 2 approved]Etienne Joly0Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse, CNRS, Toulouse, 31000, FranceThis article proposes that one should explore whether the pulmonary complications of Covid-19 can be reduced or avoided by bypassing the airway entry of the SARS-CoV-2 virus. This could possibly be achieved by injecting live SARS-CoV-2 virus intradermal (ID), subcutaneous, intra-muscular (IM) or intra-peritoneal (IP), or by targeting the virus to the digestive tract.  The effectiveness and innocuity of using those various routes could be tested very rapidly in animal models, such as Macaques, Hamsters, Ferrets or Cats.   The hope is that these experiments will reveal a route of inoculation that can reliably lead to bona-fide infections, resulting in strong immune responses, with both cellular and serological components, but with much less viral replication in the lungs. This would not only hopefully reduce the incidence of pulmonary complications in the infected subjects, but would also probably reduce the amount of virus released by them via aerosols, and thus reduce the vector of contagiosity that is hardest to control, and that probably leads most effectively to viral replication in the lungs.   If those experiments in animal models reveal that one or several routes can be used effectively to reduce pulmonary pathology, a clinical trial could be conducted in human volunteers with very low risk profiles. The ID route should probably be considered as a priority, since it could double-up as a skin test to reveal the immune status of the recipients towards the SARS-CoV-2 virus.   The course of action proposed here may possibly provide a way of taking a step ahead of the virus, and if it works as hoped, could help to end the need for confinement within a matter of months, if not weeks.https://f1000research.com/articles/9-309/v1
collection DOAJ
language English
format Article
sources DOAJ
author Etienne Joly
spellingShingle Etienne Joly
Confronting Covid-19 by exploring the possibility of vaccinating with live SARS-CoV-2 virus itself, via a route that would reduce the incidence of pulmonary complications [version 1; peer review: 2 approved]
F1000Research
author_facet Etienne Joly
author_sort Etienne Joly
title Confronting Covid-19 by exploring the possibility of vaccinating with live SARS-CoV-2 virus itself, via a route that would reduce the incidence of pulmonary complications [version 1; peer review: 2 approved]
title_short Confronting Covid-19 by exploring the possibility of vaccinating with live SARS-CoV-2 virus itself, via a route that would reduce the incidence of pulmonary complications [version 1; peer review: 2 approved]
title_full Confronting Covid-19 by exploring the possibility of vaccinating with live SARS-CoV-2 virus itself, via a route that would reduce the incidence of pulmonary complications [version 1; peer review: 2 approved]
title_fullStr Confronting Covid-19 by exploring the possibility of vaccinating with live SARS-CoV-2 virus itself, via a route that would reduce the incidence of pulmonary complications [version 1; peer review: 2 approved]
title_full_unstemmed Confronting Covid-19 by exploring the possibility of vaccinating with live SARS-CoV-2 virus itself, via a route that would reduce the incidence of pulmonary complications [version 1; peer review: 2 approved]
title_sort confronting covid-19 by exploring the possibility of vaccinating with live sars-cov-2 virus itself, via a route that would reduce the incidence of pulmonary complications [version 1; peer review: 2 approved]
publisher F1000 Research Ltd
series F1000Research
issn 2046-1402
publishDate 2020-04-01
description This article proposes that one should explore whether the pulmonary complications of Covid-19 can be reduced or avoided by bypassing the airway entry of the SARS-CoV-2 virus. This could possibly be achieved by injecting live SARS-CoV-2 virus intradermal (ID), subcutaneous, intra-muscular (IM) or intra-peritoneal (IP), or by targeting the virus to the digestive tract.  The effectiveness and innocuity of using those various routes could be tested very rapidly in animal models, such as Macaques, Hamsters, Ferrets or Cats.   The hope is that these experiments will reveal a route of inoculation that can reliably lead to bona-fide infections, resulting in strong immune responses, with both cellular and serological components, but with much less viral replication in the lungs. This would not only hopefully reduce the incidence of pulmonary complications in the infected subjects, but would also probably reduce the amount of virus released by them via aerosols, and thus reduce the vector of contagiosity that is hardest to control, and that probably leads most effectively to viral replication in the lungs.   If those experiments in animal models reveal that one or several routes can be used effectively to reduce pulmonary pathology, a clinical trial could be conducted in human volunteers with very low risk profiles. The ID route should probably be considered as a priority, since it could double-up as a skin test to reveal the immune status of the recipients towards the SARS-CoV-2 virus.   The course of action proposed here may possibly provide a way of taking a step ahead of the virus, and if it works as hoped, could help to end the need for confinement within a matter of months, if not weeks.
url https://f1000research.com/articles/9-309/v1
work_keys_str_mv AT etiennejoly confrontingcovid19byexploringthepossibilityofvaccinatingwithlivesarscov2virusitselfviaaroutethatwouldreducetheincidenceofpulmonarycomplicationsversion1peerreview2approved
_version_ 1721444936326316032